ALRN-6924 vs Plitidepsin
Head-to-head comparison of ALRN-6924 (ALRN-6924 dual MDM2/MDMX stapled p53 mimetic peptide) and Plitidepsin (Dehydrodidemnin B (Plitidepsin)) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | ALRN-6924 | Plitidepsin |
|---|---|---|
| Category | Experimental | Experimental |
| Full Name | ALRN-6924 dual MDM2/MDMX stapled p53 mimetic peptide | Dehydrodidemnin B (Plitidepsin) |
| Molecular Weight | N/A | 1110.3 Da |
| Half-Life | Hours to days depending on formulation | Approximately 44 hours |
| Amino Acids | N/A | N/A |
| Typical Dose | Varies by clinical protocol | 1.5 mg/m2 IV |
| Route | Intravenous/Subcutaneous | Intravenous |
| Purity | ≥98% | ≥98% |
| Studies Count | 40 | 240 |
| Research Status | Clinical | Clinical |
ALRN-6924 Benefits
- ✓p53 reactivation
- ✓dual MDM2/MDMX inhibition
- ✓protease resistance
- ✓tumor cell apoptosis
Plitidepsin Benefits
- ✓antineoplastic
- ✓antiviral
- ✓pro-apoptotic
- ✓anti-inflammatory
ALRN-6924 Dosing
Clinical trial protocol dosing|Intermittent administration|Research-only escalation
Plitidepsin Dosing
1.5 mg/m2 IV infusion in oncology trials|q21d or similar intermittent schedules|dose escalation and combination protocols in studies
ALRN-6924 Side Effects
- ⚠nausea
- ⚠fatigue
- ⚠myelosuppression
Plitidepsin Side Effects
- ⚠nausea
- ⚠fatigue
- ⚠transaminase elevation
Research Overview
ALRN-6924
ALRN-6924 is one of the best-known stapled peptide therapeutics and has advanced into human oncology studies. Literature shows that hydrocarbon stapling can improve target affinity, serum stability, and cellular activity for this p53-mimetic scaffold.
Plitidepsin
Plitidepsin has been studied for its ability to disrupt eEF1A-dependent pathways, induce oxidative stress, and suppress tumor cell growth. It has reached clinical oncology development and was also evaluated as a candidate against SARS-CoV-2 in the literature.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.